Delving into the Latest Updates on Novartis Pharma Services AG with Synapse

Overview

Data describing physicians’ and patients’ perspectives towards immune thrombocytopenia (ITP) management and impact of disease in Iran are limited. This ITP World Impact Survey was conducted between October 2019 and October 2020. Of the 114 patients included in the survey, 17 were aged ≤18 years. Forty-seven physicians, including 22 pediatric hematologists, participated in the survey. Fatigue and anxiety around stable platelet counts were frequent patient-reported symptoms at diagnosis and at survey completion. According to physicians, “watch-and-wait” was the preferred treatment option for mean (standard deviation) proportion of 50.1 (24.1) and 48.6 (21.8) of their adult and pediatric patients, respectively, following first diagnosis. Per adult and pediatric hematologists, the most prescribed treatments for newly diagnosed patients based on available answers were steroids (100%, n = 20/20; 89%, n = 16/18), respectively. Forty percent of adult (n = 10/25) and 38% of pediatric hematologists (n = 8/21) reported that ITP reduced patients’ quality of life. Energy levels (46%, n = 52/112) and ability to concentrate on everyday activities (42%, n = 47/113) were the most affected aspects of patients' lives. This I-WISh study in Iran underlined the negative impact of ITP on patients.

01 Jan 2022·Immunotherapy Advances

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor

Article

Author: Dranoff, Glenn ; Wavreille, Anne-Sophie ; Hu, Tiancen ; Jiang, Xiaomo ; Xu, Fangmin ; Longmire, Tyler ; Fan, Hong ; Patel, Nidhi ; Taraszka, John ; Ramesh, Radha ; Rinne, Mikael ; Miyashiro, Joy ; Pelletier, Marc ; Velez, Janelle ; Jayaraman, Pushpa ; Cremasco, Viviana ; Sabatos-Peyton, Catherine ; Schwartz, Stephanie ; Verneret, Melanie ; Lu, Hongbo ; Baker, Lisa

AbstractObjectivesSabatolimab is a humanized monoclonal antibody (hIgG4, S228P) directed against human T-cell immunoglobulin domain and mucin domain-3 (TIM-3). Herein, we describe the development and characterization of sabatolimab.MethodsSabatolimab was tested for binding to its target TIM-3 and blocking properties. The functional effects of sabatolimab were tested in T-cell killing and myeloid cell cytokine assays. Antibody-mediated cell phagocytosis (ADCP) by sabatolimab was also assessed.ResultsSabatolimab was shown to (i) enhance T-cell killing and inflammatory cytokine production by dendritic cells (DCs); (ii) facilitate the phagocytic uptake of TIM-3-expressing target cells; and (iii) block the interaction between TIM-3 and its ligands PtdSer/galectin-9.ConclusionTaken together, our results support both direct anti-leukemic effects and immune-mediated modulation by sabatolimab, reinforcing the notion that sabatolimab represents a novel immunotherapy with immuno-myeloid activity, holding promise for the treatment of myeloid cell neoplasms.

100 Deals associated with Novartis Pharma Services AG

Login to view more data

100 Translational Medicine associated with Novartis Pharma Services AG

Login to view more data